Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced ...

The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases cystic fibrosis, sickle cell disease and transfusion-dependent beta ...

Certain genotypes of α-thalassemia present with microcytosis ... of an RBC to be dyed by a variety of laboratory stains Red Blood Cell Indices Series of relationships characterizing erythrocytes ...

MDS are a group of closely related blood cancers in which there is ineffective production of healthy red blood cells ... anaemia in adult patients with beta thalassemia requiring regular RBC ...

Zynteglo was given a conditional approval in the EU on 29 May for transfusion-dependent beta thalassaemia ... regular blood transfusions to increase their levels of working red blood cells ...

The risk of developing blood cancer increases with age. The finding that a molecule from gut bacteria plays a part points to ...

Princess Margaret Cancer Center at University Health Network-led researchers constructed a detailed single-cell atlas of ...

Stanford Medicine researchers have developed a blood test capable of detecting cancers, the ways cancer resists treatments ...

Reduced levels of a critical protein are linked to devastating brain diseases like Alzheimer's, frontotemporal dementia, and ...